Edwards Lifesciences Corp: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Edwards Lifesciences Corp Unternehmen

Edwards Lifesciences Corporation is a global structural heart innovation company. The Company is engaged in patient-focused medical innovations for structural heart disease and invests in research and development to transform care for those impacted by structural heart disease. Its products are categorized into groups, including Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart (Surgical). It develops transcatheter heart valve replacement technologies designed for the minimally invasive replacement of aortic heart valves. The Edwards SAPIEN family of valves includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra, and the Edwards SAPIEN 3 Ultra RESILIA systems, are catheter-based approaches for treating severe symptomatic aortic stenosis. Its PASCAL PRECISION and Cardioband transcatheter valve repair systems are commercially available in Europe for mitral and tricuspid valve repair.

Edwards Lifesciences Corp Informationen



BörsenkürzelEW

Name des UnternehmensEdwards Lifesciences Corp

IPO-datumMar 27, 2000

CEOMr. Bernard J. Zovighian

Anzahl der mitarbeiter15800

WertpapierartOrdinary Share

GeschäftsjahresendeMar 27

AddresseOne Edwards Way

StadtIRVINE

BörseNYSE Consolidated

LandUnited States of America

Postleitzahl92614

Telefon19492502500

Websitehttps://www.edwards.com

BörsenkürzelEW

IPO-datumMar 27, 2000

CEOMr. Bernard J. Zovighian

Führungskräfte von Edwards Lifesciences Corp



Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Scott B. Ullem

Chief Financial Officer, Corporate Vice President

282.82K

+3.48%

Mr. Steven R. (Steve) Loranger

Independent Director

76.00K

+6.56%

Mr. Bernard J. Zovighian

Chief Executive Officer, Director

39.57K

+120.44%

Mr. Daniel J. Lippis

Corporate Vice President - Transcatheter Aortic Valve Replacement

21.26K

-17.30%

Mr. Daveen Chopra

Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies

19.91K

+19.18%

Mr. Paul A. Laviolette

Independent Director

11.25K

+45.71%

Dr. David T. Feinberg, M.D.

Independent Director

5.84K

+152.86%

Mr. Nicholas J. (Nick) Valeriani

Independent Chairman of the Board

--

Mr. Kieran T. Gallahue

Independent Director

--

Mr. Donald E. Bobo, Jr.

Corporate Vice President - Strategy and Corporate Development

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Scott B. Ullem

Chief Financial Officer, Corporate Vice President

282.82K

+3.48%

Mr. Steven R. (Steve) Loranger

Independent Director

76.00K

+6.56%

Mr. Bernard J. Zovighian

Chief Executive Officer, Director

39.57K

+120.44%

Mr. Daniel J. Lippis

Corporate Vice President - Transcatheter Aortic Valve Replacement

21.26K

-17.30%

Mr. Daveen Chopra

Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies

19.91K

+19.18%

Mr. Paul A. Laviolette

Independent Director

11.25K

+45.71%

Umsatzaufteilung

Währung: USDAktualisiert: Mon, Oct 6

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Transcatheter Aortic Valve Replacement

1.13B

73.81%

Surgical Heart Valve Therapy

266.80M

17.41%

Transcatheter Mitral and Tricuspid Therapies

134.50M

8.78%

Nach RegionUSD

Name

Umsatz

Anteil

United States

889.70M

58.07%

Europe

378.20M

24.68%

Rest of the world

169.00M

11.03%

Japan

95.30M

6.22%

Nach Geschäftsbereich

Nach Region

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Transcatheter Aortic Valve Replacement

1.13B

73.81%

Surgical Heart Valve Therapy

266.80M

17.41%

Transcatheter Mitral and Tricuspid Therapies

134.50M

8.78%

Aktionärsstatistik

Aktualisiert: Sat, Aug 16

Aktionäre

Aktionärstypen

Aktionäre

Anteil

The Vanguard Group, Inc.

11.88%

BlackRock Institutional Trust Company, N.A.

5.26%

State Street Investment Management (US)

4.37%

JP Morgan Asset Management

3.42%

Wellington Management Company, LLP

3.38%

Andere

71.70%

Aktionäre

Anteil

The Vanguard Group, Inc.

11.88%

BlackRock Institutional Trust Company, N.A.

5.26%

State Street Investment Management (US)

4.37%

JP Morgan Asset Management

3.42%

Wellington Management Company, LLP

3.38%

Andere

71.70%

Aktionärstypen

Aktionäre

Anteil

Investment Advisor

43.44%

Investment Advisor/Hedge Fund

29.71%

Hedge Fund

6.65%

Research Firm

2.23%

Pension Fund

2.17%

Bank and Trust

1.92%

Sovereign Wealth Fund

1.35%

Individual Investor

0.92%

Endowment Fund

0.82%

Andere

10.79%

Institutionelle Beteiligung



Aktualisiert: Wed, Oct 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q3

2562

521.87M

88.89%

-32.35M

2025Q2

2595

528.14M

89.95%

-20.66M

2025Q1

2628

535.29M

91.24%

-19.91M

2024Q4

2597

531.64M

90.42%

-4.10M

2024Q3

2568

511.38M

84.93%

-20.94M

2024Q2

2559

522.19M

86.68%

-12.58M

2024Q1

2572

518.82M

86.18%

-12.08M

2023Q4

2573

509.93M

84.08%

-27.42M

2023Q3

2530

522.96M

86.03%

-18.75M

2023Q2

2517

523.54M

86.35%

-20.02M

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

The Vanguard Group, Inc.

69.74M

11.88%

+793.20K

+1.15%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

30.89M

5.26%

-1.39M

-4.31%

Jun 30, 2025

State Street Investment Management (US)

25.63M

4.37%

-149.08K

-0.58%

Jun 30, 2025

JP Morgan Asset Management

20.09M

3.42%

+3.72M

+22.71%

Jun 30, 2025

Wellington Management Company, LLP

19.83M

3.38%

-9.31M

-31.95%

Jun 30, 2025

Jennison Associates LLC

11.67M

1.99%

+1.58M

+15.71%

Jun 30, 2025

Citadel Advisors LLC

12.73M

2.17%

-650.39K

-4.86%

Jun 30, 2025

Geode Capital Management, L.L.C.

12.72M

2.17%

+45.55K

+0.36%

Jun 30, 2025

Walter Scott & Partners Ltd.

8.91M

1.52%

-150.07K

-1.66%

Jun 30, 2025

Union Investment Privatfonds GmbH

8.59M

1.46%

+4.67M

+119.31%

Jun 30, 2025

Verbundene ETFs



Aktualisiert: Mon, Oct 6

Name

Anteil

iShares U.S. Medical Devices ETF

4.79%

Future Fund Long/Short ETF

3.68%

Hennessy Sustainable ETF

3.27%

Global X Aging Population ETF

3.15%

iShares Health Innovation Active ETF

3.12%

First Trust Indxx Medical Devices ETF

2.17%

Tema Heart & Health ETF

2.16%

SPDR S&P Health Care Equipment ETF

1.95%

PGIM Jennison Better Future ETF

1.93%

Invesco S&P 500 Equal Weight Health Care ETF

1.77%

iShares U.S. Medical Devices ETF

Anteil4.79%

Future Fund Long/Short ETF

Anteil3.68%

Hennessy Sustainable ETF

Anteil3.27%

Global X Aging Population ETF

Anteil3.15%

iShares Health Innovation Active ETF

Anteil3.12%

First Trust Indxx Medical Devices ETF

Anteil2.17%

Tema Heart & Health ETF

Anteil2.16%

SPDR S&P Health Care Equipment ETF

Anteil1.95%

PGIM Jennison Better Future ETF

Anteil1.93%

Invesco S&P 500 Equal Weight Health Care ETF

Anteil1.77%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Art

Verhältnis

May 07, 2020

Split

1→3

Datum

Art

Verhältnis

May 07, 2020

Split

1→3